Top

Published in:

01-11-2007

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease

Authors: Elaine M. Castilow, Matthew R. Olson, Steven M. Varga

Published in: Immunologic Research | Issue 1-3/2007

Abstract

Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection in infants and children worldwide. In addition, RSV causes serious disease in elderly and immune compromised individuals. RSV infection of children previously immunized with a formalin-inactivated (FI)-RSV vaccine is associated with enhanced disease and pulmonary eosinophilia that is believed to be due to an exaggerated memory Th2 response. As a consequence, there is currently no licensed RSV vaccine and detailed studies directed towards prevention of vaccine-associated disease are a critical first step in the development of a safe and effective vaccine. The BALB/c mouse model of RSV infection faithfully mimics the human respiratory disease. Mice previously immunized with either FI-RSV or a recombinant vaccinia virus (vv) that expresses the attachment (G) glycoprotein exhibit extensive lung inflammation and injury, pulmonary eosinophilia, and enhanced disease following challenge RSV infection. CD4 T cells secreting Th2 cytokines are necessary for this response because their depletion eliminates eosinophilia. Intriguing recent studies have demonstrated that RSV-specific CD8 T cells can inhibit Th2-mediated pulmonary eosinophilia in vvG-primed mice by as yet unknown mechanisms. Information gained from the animal models will provide important information and novel approaches for the rational design of a safe and efficacious RSV vaccine.

Chanock RM, Roizman B, Myers R. Recovery from infants with respiratory illness of a virus related to chimpanzee coryzal agent (CCA). I. Isolation, properties and characterization. Am J Hyg 1957;66:281–90.PubMed

Heilman CA. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990;161:402–6.PubMed

Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980–1996. Jama 1999;15:1440–6.CrossRef

Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. Jama 2003;2:179–86.CrossRef

Ogra PL. Respiratory syncytial virus: the virus, the disease and the immune response. Paediatr Respir Rev 2004;5:S119–26.PubMedCrossRef

Welliver RC, Wong DT, Sun M, Middleton E Jr, Vaughan RS, Ogra PL. The development of respiratory syncytial virus-specific IgE and the release of histamine in nasopharyngeal secretions after infection. N Engl J med 1981;15:841–6.CrossRef

Garofalo R, Kimpen JL, Welliver RC, Ogra PL. Eosinophil degranulation in the respiratory tract during naturally acquired respiratory syncytial virus infection. J Pediatr 1992;1:28–32.

Garofalo R, Dorris A, Ahlstedt S, Welliver RC. Peripheral blood eosinophil counts and eosinophil cationic protein content of respiratory secretions in bronchiolitis: relationship to severity of disease. Pediatr Allergy Immunol 1994;2:111–7.CrossRef

Sigurs N. Epidemiologic and clinical evidence of a respiratory syncytial virus-reactive airway disease link. Am J Respir Crit Care Med 2001;3 Pt 2:S2–6.

10.

Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543–6.PubMed

11.

Agius G, Dindinaud G, Biggar RJ, Peyre R, Vaillant V, Ranger S, Poupet JY, Cisse MF, Castets M. An epidemic of respiratory syncytial virus in elderly people: clinical and serological findings. J Med Virol 1990;2:117–27.CrossRef

12.

Falsey AR, Treanor JJ, Betts RF, Walsh EE. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. J Am Geriatr Soc 1992;40:115–9.PubMed

13.

Falsey AR, Cunningham CK, Barker WH, Kouides RW, Yuen JB, Menegus M, et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995;352:389–94.

14.

Osterweil D, Norman D. An outbreak of an influenza-like illness in a nursing home. J Am Geriatr Soc 1990;6:659–62.

15.

Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, et al. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 1986;315:77–81.

16.

Harrington RD, Hooton TM, Hackman RC, Storch GA, Osborne B, Gleaves CA, Benson A, Meyers JD. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992;165:987–93.PubMed

17.

Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005;17:1749–59.CrossRef

18.

Belshe RB, Van Voris LP, Mufson MA. Parenteral administration of live respiratory syncytial virus vaccine: results of a field trial. J Infect Dis 1982;145:311–9.PubMed

19.

Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. Respiratory virus immunization I. A field trial of two inactivated respiratory virus vaccines;an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 1969;352:435–48.

20.

Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969;89:405–21.PubMed

21.

Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine Am J Epidemiol 1969;89:422–34.

22.

Chin JC, Magoffin RL, Shearer LA, Schieble JH, Lennette EH. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969;89:449–63.PubMed

23.

Johnson TR, Graham BS. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 1999;73:8485–95.PubMed

24.

Johnson TR, Teng MN, Collins PL, Graham BS. Respiratory syncytial virus (RSV) G Glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV. J Virol 2004;11:6024–32.CrossRef

25.

Johnson TR, Varga SM, Braciale TJ, Graham BS. Vβ14⁺ T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV. J Virol 2004;16:8753–60.CrossRef

26.

Waris ME, Tsou C, Erdman DD, Zaki SR, Anderson LJ. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996;70:2852–60.PubMed

27.

Lampinen M, Carlson M, Hakansson LD, Venge P. Cytokine-regulated accumulation of eosinophils in inflammatory disease. Allergy 2004;8:793–805.CrossRef

28.

Power UF, Huss T, Michaud V, Plotnicky-Gilquin H, Bonnefoy J-Y, Nguyen TN. Differential histopathology and chemokine gene expression in lung tissues following respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV- or BBG2Na-immunized mice. J Virol 2001;75:12421–30.PubMedCrossRef

29.

Johnson TR, Parker RA, Johnson JE, Graham BS. IL-13 is sufficient for respiratory syncytial virus G glycoprotein-induced eosinophilia after respiratory syncytial virus challenge. J Immunol 2003;4:2037–45.

30.

Connors M, Giese NA, Kulkarni AB, Firestone C-Y, Morse HC, Murphy BR. Enhanced pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of interleukin-4 (IL-4) and IL-10. J Virol 1994;68:5321–5.PubMed

31.

Polack FP, Teng MN, Collins PL, Prince GA, Exner M, Regele H, et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002;6:859–65.

32.

Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986;2:197–202.

33.

Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988;8:1595–7.

34.

Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, et al. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 2006;8:905–7.

35.

Acharya AS, Manning JM. Reaction of glycolaldehyde with proteins: latent crosslinking potential of alpha-hydroxyaldehydes. Proc Natl Acad Sci USA 1983;12:3590–4.CrossRef

36.

Adams S, Green P, Claxton R, Simcox S, Williams MV, Walsh K, et al. Reactive carbonyl formation by oxidative and non-oxidative pathways Front Biosci 2001;6:A17–24.

37.

Brodsky AL. Atypical measles. Severe illness in recipients of killed measles virus vaccine upon exposure to natural infection. Jama 1972;11:1214–6.

38.

Cherry JD, Feigin RD, Lobes LA Jr, Shackelford PG. Atypical measles in children previously immunized with attenuated measles virus vaccines. Pediatrics 1972;5:712–7.

39.

St Geme JW Jr, George BL, Bush BM. Exaggerated natural measles following attenuated virus immunization. Pediatrics 1976;1:148–9.

40.

Innis BL, Snitbhan R, Kunasol P, Laorakpongse T, Poopatanakool W, Kozik CA, et al. Protection against hepatitis A by an inactivated vaccine. Jama 1994;17:1328–34.

41.

Melnick JL. Current status of poliovirus infections. Clin Microbiol Rev 1996;3:293–300.

42.

Werzberger A, Mensch B, Kuter B, Brown L, Lewis J, Sitrin R, et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. New Engl J Med 1992;7:453–7.

43.

Hancock GE, Speelman DJ, Heers K, Bortell E, Smith J, Cosco C. Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus. J Virol 1996;11:7783–91.

44.

Hussell T, Georgiou A, Sparer TE, Matthews S, Pala P, Openshaw PJM. Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. J Immunol 1998;161:6215–22.PubMed

45.

Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 1998;74:2871–80.

46.

Openshaw PJM, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992;4:493–500.PubMedCrossRef

47.

Srikiatkhachorn A, Braciale TJ. Virus-specific memory and effector T lymphocytes exhibit different cytokine responses to antigens during experimental murine respiratory syncytial virus infection. J Virol 1997;71:678–85.PubMed

48.

Hussell T, Spender LC, Georgiou A, O’Garra A, Openshaw PJM. Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. J Gen Virol 1996;77:2447–55.PubMedCrossRef

49.

Matthews SP, Tregoning JS, Coyle AJ, Hussell T, Openshaw PJ. Role of CCL11 in eosinophilic lung disease during respiratory syncytial virus infection. J Virol 2005;4:2050–7.CrossRef

50.

Srikiatkhachorn A, Chang W, Braciale TJ. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J Virol 1999;73:6590–7.PubMed

51.

Tebbey PW, Hagen M, Hancock GE. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 1998;188:1967–72.PubMedCrossRef

52.

Varga SM, Wang X, Welsh RM, Braciale TJ. Immunopathology in RSV infection is mediated by a discrete oligoclonal subset of antigen-specific CD4⁺ T cells. Immunity 2001;15:637–46.PubMedCrossRef

53.

Varga SM, Wissinger EL, Braciale TJ. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4⁺ T cell responses. J Immunol 2000;165:6487–95.PubMed

54.

Callard RE, Mattews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol Today 1996;17:108–10.PubMedCrossRef

55.

Lohning M, Stroehmann A, Coyle AJ, Grogan JL, Lin S, Gutierrez-Ramos JC, Levinson D, et al. T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. Proc Natl Acad Sci USA 1998;12:6930–5.

56.

Walzl G, Matthews S, Kendall S, Gutierrez-Ramos JC, Coyle AJ, Openshaw PJM, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med 2001;193:785–92.PubMedCrossRef

57.

Bangham CRM, Openshaw PJM, Ball LA, King AMQ, Wertz GW, Askonas BA. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J Immunol 1986;137:3973–77.PubMed

58.

Pemberton RM, Cannon MJ, Openshaw PJ, Ball LA, Wertz GW, Askonas BA. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J Gen Virol 1987;68:2177–82.PubMed

59.

Alwan WH, Kozlowska WJ, Openshaw PJM. Distinct types of lung disease caused by functional subsets of antiviral T cells. J Exp Med. 1994;81–9.

60.

Hussell T, Baldwin CJ, O’Garra A, Openshaw PJM. CD8⁺ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 1997;27:3341–9.PubMedCrossRef

61.

Srikiatkhachorn A, Braciale TJ. Virus-specific CD8⁺ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J Exp Med 1997;186:421–32.PubMedCrossRef

62.

Connors M, Kulkarni AB, Firestone C-Y, Holmes KL, Morse HC, Sotnikov AV, et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4⁺ T cells. J Virol 1992;66:7444–51.PubMed

63.

Hancock GE, Tebbey PW, Scheuer CA, Pryharski KS, Heers KM, LaPierre NA. Immune responses to the nonglycosylated ectodomain of respiratory syncytial virus attachment glycoprotein mediate pulmonary eosinophilia in inbred strains of mice with different MHC haplotypes. J Med Virol 2003;2:301–8.CrossRef

64.

Muller D, Koller BH, Whitton JL, LaPan KE, Brigman KK, Frelinger JA. LCMV-specific, class II-restricted cytotoxic T cells in β₂-microglobulin-deficient mice. Science 1992;255:1576–8.PubMedCrossRef

65.

Quinn DG, Zajac AJ, Frelinger JA, Muller D. Transfer of lymphocytic choriomeningitis disease in β₂-microglobulin-deficient mice by CD4⁺ T cells. Int Immunol 1993;5:1193–8.PubMedCrossRef

66.

Fernandez-Botran R, Sanders VM, Mosmann TR, Vitetta ES. Lymphokine-mediated regulation of the proliferative response of clones of T helper 1 and T helper 2 cells. J Exp Med 1988;2:543–58.CrossRef

67.

Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;12:4245–52.

68.

McMenamin C, Holt PG. The natural immune response to inhaled soluble protein antigens involves major histocompatibility complex (MHC) class I-restricted CD8+ T cell-mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J Exp Med 1993;3:889–99.CrossRef

69.

Stock P, Kallinich T, Akbari O, Quarcoo D, Gerhold K, Wahn U, Umetsu DT, Hamelmann E. CD8⁺ T cells regulate immune responses in a murine model of allergen-induced sensitization and airway inflammation. Eur J Immunol 2004;7:1817–27.CrossRef

70.

Suzuki M, Maghni K, Molet S, Shimbara A, Hamid QA, Martin JG. IFN-gamma secretion by CD8T cells inhibits allergen-induced airway eosinophilia but not late airway responses. J Allergy Clin Immunol 2002;5:803–9.CrossRef

71.

Allakhverdi Z, Lamkhioued B, Olivenstein R, Hamid Q, Renzi PM. CD8 depletion-induced late airway response is characterized by eosinophilia, increased eotaxin, and decreased IFN-gamma expression in rats. Am J Respir Crit Care Med 2000;3 Pt 1:1123–31.

72.

Medoff BD, Sauty A, Tager AM, Maclean JA, Smith RN, Mathew A, et al. IFN-γ-inducible protein 10 (CXCL10) contributes to airway hyperreactivity and airway inflammation in a mouse model of asthma. J Immunol 2002;10:5278–86.

73.

Fishaut M, Tubergen D, McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980;2:179–86.

74.

Graham BS, Bunton LA, Wright PF, Karzon DT. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991;88:1026–33.PubMed

75.

Ostler T, Davidson W, Ehl S. Virus clearance and immunopathology by CD8⁺ T cells during infection with respiratory syncytial virus are mediated by IFN-γ. Eur J Immunol 2002;8:2117–23.CrossRef

76.

Rutigliano JA, Graham BS. Prolonged Production of TNF-α Exacerbates Illness during Respiratory Syncytial Virus Infection. J Immunol 2004;5:3408–17.

77.

Chang J, Braciale TJ. Respiratory syncytial virus infection suppresses lung CD8⁺ T-cell effector activity and peripheral CD8⁺ T-cell memory in the respiratory tract. Nat Med 2002;8:54–60.PubMedCrossRef

78.

Kulkarni AB, Collins PL, Bacik I, Yewdell JW, Bennink JR, Crowe JE Jr, et al. Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus. J Virol 1995;2:1261–4.

79.

Lee S, Miller SA, Wright DW, Rock MT, Crowe JE Jr. Tissue-Specific Regulation of CD8+ T Lymphocyte Immunodominance in Respiratory Syncytial Virus Infection. J Virol 2006;81:2349–58. PubMedCrossRef

80.

Chang J, Srikiatkhachorn A, Braciale TJ. Visualization and characterization of respiratory syncytial virus F-specific CD8⁺ T cells during experimental virus infection. J Immunol 2001;167:4254–60. PubMed

81.

Rutigliano JA, Rock MT, Johnson AK, Crowe JE Jr, Graham BS. Identification of an H-2D(b)-restricted CD8+ cytotoxic T lymphocyte epitope in the matrix protein of respiratory syncytial virus. Virology 2005;2:335–43. CrossRef

82.

Lukens MV, Claassen EA, de Graaff PM, van Dijk ME, Hoogerhout P, Toebes M, et al. Characterization of the CD8+ T cell responses directed against respiratory syncytial virus during primary and secondary infection in C57BL/6 mice. Virology 2006;1:157–68.

83.

Yoshida M, Leigh R, Matsumoto K, Wattie J, Ellis R, O’Byrne PM, et al. Effect of interferon-gamma on allergic airway responses in interferon-gamma-deficient mice. Am J Respir Crit Care Med 2002;4:451–6.

84.

Myers L, Croft M, Kwon BS, Mittler RS, Vella AT. Peptide-specific CD8 T regulatory cells use IFN-gamma to elaborate TGF-beta-based suppression. J Immunol 2005;12:7625–32.

85.

Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 2006;2:896–904.

86.

Taylor A, Verhagen J, Blaser K, Akdis M, Akdis CA. Mechanisms of immune suppression by interleukin-10 and transforming growth factor-beta: the role of T regulatory cells. Immunology 2006;4:433–42. CrossRef

87.

Bienvenu B, Martin B, Auffray C, Cordier C, Becourt C, Lucas B. Peripheral CD8+CD25+ T lymphocytes from MHC class II-deficient mice exhibit regulatory activity. J Immunol 2005;1:246–53.

88.

Horwitz DA, Zheng SG, Gray JD. The role of the combination of IL-2 and TGF-beta or IL-10 in the generation and function of CD4+ CD25+ and CD8+ regulatory T cell subsets. J Leukoc Biol 2003;4:471–8. CrossRef

89.

Aung S, Rutigliano JA, Graham BS. Alternative mechanisms of respiratory syncytial virus clearance in perforin knockout mice lead to enhanced disease. J Virol 2001;75:9918–24. PubMedCrossRef

90.

Alvarez R, Tripp RA. The immune response to human metapneumovirus is associated with aberrant immunity and impaired virus clearance in BALB/c mice. J Virol 2005;10:5971–8. CrossRef

Title: Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease
Authors: Elaine M. Castilow
Matthew R. Olson
Steven M. Varga
Publication date: 01-11-2007
Publisher: Humana Press Inc
Published in: Immunologic Research / Issue 1-3/2007
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI: https://doi.org/10.1007/s12026-007-0071-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1-3/2007

The regulation of dendritic cell function by calcium-signaling and its inhibition by microbial pathogens

Transcriptional control of complement receptor gene expression

Immunology at The University of Iowa

PIP3 pathway in regulatory T cells and autoimmunity

Strategies for differentiating embryonic stem cells (ESC) into insulin-producing cells and development of non-invasive imaging techniques using bioluminescence

Characterization of splenic CD21hi T2 B cells